News

Cemiplimab is revolutionizing treatment for high-risk cutaneous squamous cell carcinoma, bridging gaps in care and improving patient outcomes.

Explore the intricate link between dermatology and psychiatric disorders, revealing how mental health impacts skin conditions and treatment approaches.

The findings reinforce dupilumab as a safe, long-term cornerstone therapy for pediatric AD, with emerging flexibility in treatment scheduling.

Azitra reveals promising preclinical results for ATR-01, a novel treatment targeting ichthyosis vulgaris, paving the way for future clinical trials.

Emerging biologic combinations may open a new therapeutic frontier for severe hidradenitis suppurativa (HS) that fails to respond to conventional and single-pathway biologics.

The resubmission includes additional data and analyses addressing prior FDA concerns and is now classified as a complete response under a Class II review.

Experts discuss the OX40 pathway's potential to transform atopic dermatitis treatment, addressing unmet needs and promising new therapies for better patient outcomes.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the approval of cemiplimab as adjuvant immunotherapy for high-risk CSCC, FDA safety communication on RF microneedling, dermatologists' role in breast cancer awareness, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.

In the ARCADIA LTE, nemolizumab maintained significant and progressive improvements in skin and itch outcomes for up to 104 weeks.

This review of the latest dermatologic studies highlights new research on hidradenitis suppurativa, including associated pediatric comorbidities, CO2 laser treatment, impact on sexual health, and more.

Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.

The CHMP opinion follows recent US FDA approval, positioning Libtayo as the first immunotherapy approved for adjuvant treatment in high-risk CSCC.

Explore essential insights on breast cancer diagnosis and dermatology, highlighting key practices for early detection and patient care.

The episode underscores the clinical value of listening to patient advocates who bring firsthand understanding of disease impact.

Andrew Mastro, MS, PA-C, moderated a recent Dermatology Times Case-Based Roundtable event to present 3 complex cases of moderate to severe psoriasis treated with biologics.

FDA warns of serious risks associated with RF microneedling, urging patient education and careful provider training to ensure safety in aesthetic dermatology.

Through 3 complex cases, participants explored practical ways to integrate agents like clascoterone and tazarotene into daily practice.

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Explore the critical role of dermatologists in managing cutaneous toxicities from breast cancer therapies, enhancing patient quality of life and treatment outcomes.

Vimal Prajapati, MD, FRCPC, DABD, highlights guselkumab’s ability to achieve high levels of skin clearance in pediatric patients with moderate to severe plaque psoriasis.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

The trial evaluates ritlecitinib's efficacy for severe alopecia areata, utilizing innovative external placebo controls for enhanced patient outcomes.

Kachiu Lee, MD, MPH, FAAD, shares insights on aesthetic dermatology at the 2025 PDPA Keystone, emphasizing trust and communication over technology for optimal results.

Researchers found that while 96% of respondents use social media daily, most dermatologic information encountered online remains inaccurate or non-evidence-based.

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

Mark Kaufmann, MD, discusses how patient realities shape psoriasis treatment choices.